CoChat

SGLT inhibitors on weight and body mass: A meta‐analysis of 116 randomized‐controlled trials

Cheong, Alex Jia Yang, Teo, Yao Neng, Teo, Yao Hao, Syn, Nicholas L., Ong, How Ting, Ting, Adriel Z. H., Chia, Alys Z. Q., Chong, Elliot Yeung, Chan, Mark Y., Lee, Chi‐Hang, Lim, Amanda Yuan Ling, Kong, William K. F., Wong, Raymond C. C., Chai, Ping, Sia, Ching‐Hui · 2022 · Obesity
Cited by 99

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Objective: Multiple trials have demonstrated the metabolic effects of sodium/glucose cotransporter 2 (SGLT2) inhibitors in patients regardless of diabetes status, and recent trials have been conducted on the combined sodium/glucose cotransporter 1 and sodium/glucose cotransporter 2 (SGLT1/SGLT2) inhibitors. Therefore, a meta‐analysis was conducted to investigate the weight reduction effects and dose‐response relationship of SGLT inhibitors and to assess the relative efficacy of SGLT1/SGLT2 inhibitors. Methods: Four electronic databases (PubMed, Embase, Cochrane, and Scopus) were searched on November 21, 2020, for articles published from January 1, 2000, up to November 21, 2020. Results: In total, 116 randomized‐controlled trials were included, with a combined cohort of 98,497 patients. Overall, patients had a mean weight reduction of −1.79 kg (95% CI: −1.93 to −1.66, p < 0.001) compared with placebo. This effect was observed across diabetes status, duration of follow‐up, various comorbidities, and all SGLT drug types. Mean BMI changes were −0.71 kg/m 2 (95% CI: −0.94 to −0.47, p < 0.001) compared with placebo. Canagliflozin, empagliflozin, sotagliflozin, and licogliflozin showed a dose‐response relationship for mean weight change. Compared with SGLT2 inhibitors, SGLT1/SGLT2 inhibitors had a significantly larger reduction in weight. Conclusions: SGLT inhibitors demonstrated weight reduction benefits in this meta‐analysis. Further studies are needed to clarify their role in weight management.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/oby.23331

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 99

Metadata

Authors
Cheong, A. J. Y., Teo, Y. N., Teo, Y. H., Syn, N. L., Ong, H. T., Ting, A. Z. H., Chia, A. Z. Q., Chong, E. Y., Chan, M. Y., Lee, C., Lim, A. Y. L., Kong, W. K. F., Wong, R. C. C., Chai, P., & Sia, C.
Venue
Obesity
Publisher
Wiley
Published
2021-12-21
Volume
30
Issue
1
Pages
117-128
ISSN
  • 1930-7381 (ISSN-L)
  • 1930-739X
OpenAlex
W4200345605
Cited by
99
References
15
FWCI
7.17
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SGLT inhibitors on weight and body mass: A meta‐analysis of 116 randomized‐controlled trials. https://app.cochat.ai/papers/10.1002/oby.23331
The paper
Cheong, A. J. Y., Teo, Y. N., Teo, Y. H., Syn, N. L., Ong, H. T., Ting, A. Z. H., Chia, A. Z. Q., Chong, E. Y., Chan, M. Y., Lee, C., Lim, A. Y. L., Kong, W. K. F., Wong, R. C. C., Chai, P., & Sia, C. (2022). SGLT inhibitors on weight and body mass: A meta‐analysis of 116 randomized‐controlled trials. Obesity. https://doi.org/10.1002/oby.23331

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.